JPWO2019209995A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019209995A5
JPWO2019209995A5 JP2020560230A JP2020560230A JPWO2019209995A5 JP WO2019209995 A5 JPWO2019209995 A5 JP WO2019209995A5 JP 2020560230 A JP2020560230 A JP 2020560230A JP 2020560230 A JP2020560230 A JP 2020560230A JP WO2019209995 A5 JPWO2019209995 A5 JP WO2019209995A5
Authority
JP
Japan
Prior art keywords
antibody
binding fragment
antigen
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020560230A
Other languages
Japanese (ja)
Other versions
JP7332627B2 (en
JP2021521843A (en
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/028987 external-priority patent/WO2019209995A2/en
Publication of JP2021521843A publication Critical patent/JP2021521843A/en
Publication of JPWO2019209995A5 publication Critical patent/JPWO2019209995A5/ja
Priority to JP2023131429A priority Critical patent/JP2023166402A/en
Application granted granted Critical
Publication of JP7332627B2 publication Critical patent/JP7332627B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (22)

腫瘍壊死因子様タンパク質１Ａ（ＴＬ１Ａ）に結合する抗体または抗原結合フラグメントであって、
（ｉ）重鎖相補性決定領域１（ＨＣＤＲ１）、重鎖相補性決定領域２（ＨＣＤＲ２）、および重鎖相補性決定領域３（ＨＣＤＲ３）を含む重鎖可変領域であって、ここで、
（ａ）ＨＣＤＲ１は、ＳＥＱ ＩＤ ＮＯ：５５３によって記載されるアミノ酸配列を含み、
（ｂ）ＨＣＤＲ２は、ＳＥＱ ＩＤ ＮＯ：５５４～５６４、または５７４～５７７のいずれか１つによって記載されるアミノ酸配列を含み、および、
（ｃ）ＨＣＤＲ３は、ＳＥＱ ＩＤ ＮＯ：５６５～５６８、または５７９～５８１のいずれか１つによって記載されるアミノ酸配列を含む、
重鎖可変領域と、
（ｉｉ）軽鎖相補性決定領域１（ＬＣＤＲ１）、軽鎖相補性決定領域２（ＬＣＤＲ２）、および軽鎖相補性決定領域３（ＬＣＤＲ３）を含む軽鎖可変領域であって、ここで、
（ａ）ＬＣＤＲ１は、ＳＥＱ ＩＤ ＮＯ：５６９または５７０のいずれか１つによって記載されるアミノ酸配列を含み、
（ｂ）ＬＣＤＲ２は、ＳＥＱ ＩＤ ＮＯ：４８８によって記載されるアミノ酸配列を含み、および、
（ｃ）ＬＣＤＲ３は、ＳＥＱ ＩＤ ＮＯ：５７２によって記載されるアミノ酸配列を含む、
軽鎖可変領域と、
を含む、抗体または抗原結合フラグメント。 An antibody or antigen-binding fragment that binds to tumor necrosis factor-like protein 1A ( TL1A ) .
(I) Heavy chain complementarity determining regions 1 (HCDR1), heavy chain complementarity determining regions 2 (HCDR2), and heavy chain complementarity determining regions 3 (HCDR3).
(A) HCDR1 comprises the amino acid sequence described by SEQ ID NO: 553.
(B) HCDR2 comprises the amino acid sequence described by any one of SEQ ID NO: 554-564 , or 574-577 , and
(C) HCDR3 comprises the amino acid sequence described by any one of SEQ ID NO: 565-568 or 579-581.
Heavy chain variable region and
(Ii) A light chain variable region comprising a light chain complementarity determining region 1 (LCDR1), a light chain complementarity determining region 2 (LCDR2), and a light chain complementarity determining region 3 (LCDR3).
( A ) LCDR1 comprises the amino acid sequence described by any one of S EQ ID NO: 569 or 570.
( B ) LCDR2 comprises the amino acid sequence described by SEQ ID NO: 488 and
( C ) LCDR3 comprises the amino acid sequence described by SEQ ID NO: 572 .
Light chain variable region and
An antibody or antigen binding fragment, including. ＨＣＤＲ２は、ＳＥＱ ＩＤ ＮＯ：５５４によって記載されるアミノ酸配列を含む、請求項１に記載の抗体または抗原結合フラグメント。HCDR2 is the antibody or antigen binding fragment of claim 1, comprising the amino acid sequence described by SEQ ID NO: 554. ＨＣＤＲ２は、ＳＥＱ ＩＤ ＮＯ：５５５によって記載されるアミノ酸配列を含む、請求項１に記載の抗体または抗原結合フラグメント。 HCDR2 is the antibody or antigen binding fragment of claim 1, comprising the amino acid sequence described by SEQ ID NO: 555. ＨＣＤＲ３は、ＳＥＱ ＩＤ ＮＯ：５６５によって記載されるアミノ酸配列を含む、請求項１－３のいずれか１つに記載の抗体または抗原結合フラグメント。 The antibody or antigen-binding fragment according to any one of claims 1-3, wherein HCDR3 comprises the amino acid sequence described by SEQ ID NO: 565. ＨＣＤＲ３は、ＳＥＱ ＩＤ ＮＯ：５６６によって記載されるアミノ酸配列を含む、請求項１－３のいずれか１つに記載の抗体または抗原結合フラグメント。 The antibody or antigen-binding fragment according to any one of claims 1-3, wherein HCDR3 comprises the amino acid sequence described by SEQ ID NO: 566. ＬＣＤＲ１は、ＳＥＱ ＩＤ ＮＯ：５６９によって記載されるアミノ酸配列を含む、請求項１－５のいずれか１つに記載の抗体または抗原結合フラグメント。 The antibody or antigen-binding fragment according to any one of claims 1-5, wherein LCDR1 comprises the amino acid sequence described by SEQ ID NO: 569. 前記抗体または抗原結合フラグメントは、（ｉ）キメラ抗体またはキメラ抗原結合フラグメント、あるいは、（ｉｉ）ヒト化抗体またはヒト化抗原結合フラグメントである、請求項１－６のいずれか１つに記載の抗体または抗原結合フラグメント。 The antibody according to any one of claims 1-6, wherein the antibody or antigen-binding fragment is (i) a chimeric antibody or a chimeric antigen-binding fragment, or (ii) a humanized antibody or a humanized antigen-binding fragment. Or an antigen binding fragment. 前記抗体または抗原結合フラグメントは、ヒト化抗体またはヒト化抗原結合フラグメントである、請求項７に記載の抗体または抗原結合フラグメント。 The antibody or antigen-binding fragment according to claim 7, wherein the antibody or antigen-binding fragment is a humanized antibody or a humanized antigen-binding fragment. 前記抗体はＩｇＧ抗体である、請求項１－８のいずれか１つに記載の抗体または抗原結合フラグメント。 The antibody or antigen-binding fragment according to any one of claims 1-8, wherein the antibody is an IgG antibody. 前記抗体または抗原結合フラグメントは、Ｆａｂ、Ｆ（ａｂ） The antibody or antigen binding fragment is Fab, F (ab). ２2 、単一ドメイン抗体、単鎖可変フラグメント（ｓｃＦｖ）、またはナノボディである、請求項１－９のいずれか１つに記載の抗体または抗原結合フラグメント。The antibody or antigen binding fragment according to any one of claims 1-9, which is a single domain antibody, a single chain variable fragment (scFv), or a Nanobody. 前記抗体または抗原結合フラグメントは、Ｔリンパ球からのインターフェロンγのＴＬ１Ａ誘導分泌を阻害する、請求項１－１０のいずれか１つに記載の抗体または抗原結合フラグメント。 The antibody or antigen-binding fragment according to any one of claims 1-10, wherein the antibody or antigen-binding fragment inhibits TL1A-induced secretion of interferon γ from T lymphocytes. 請求項１－１１のいずれか１つに記載の抗体または抗原結合フラグメントと、薬学的に許容可能な賦形剤、担体、または希釈剤とを含む、医薬組成物。 A pharmaceutical composition comprising the antibody or antigen binding fragment according to any one of claims 1-11 and a pharmaceutically acceptable excipient, carrier, or diluent. 炎症性腸疾患、クローン病、または大腸炎の処置のための薬剤の製造における、請求項１－１１のいずれか１つに記載の抗体または抗原結合フラグメントの使用。 Use of an antibody or antigen-binding fragment according to any one of claims 1-11 in the manufacture of an agent for the treatment of inflammatory bowel disease, Crohn's disease, or colitis. 炎症性腸疾患の処置のための薬剤の製造における、請求項１３に記載の使用。 13. The use according to claim 13 in the manufacture of an agent for the treatment of inflammatory bowel disease. クローン病の処置のための薬剤の製造における、請求項１３に記載の使用。 13. The use according to claim 13 in the manufacture of an agent for the treatment of Crohn's disease. 大腸炎の処置のための薬剤の製造における、請求項１３に記載の使用。 13. The use according to claim 13 in the manufacture of a drug for the treatment of colitis. 炎症性腸疾患、クローン病、または大腸炎の処置に使用するための、請求項１２に記載の医薬組成物。 12. The pharmaceutical composition according to claim 12, for use in the treatment of inflammatory bowel disease, Crohn's disease, or colitis. Ｔリンパ球によるインターフェロンγ分泌の防止または減少のための薬剤の製造における、請求項１－１１のいずれか１つに記載の抗体または抗原結合フラグメントの使用。 Use of the antibody or antigen-binding fragment according to any one of claims 1-11 in the manufacture of a drug for the prevention or reduction of interferon gamma secretion by T lymphocytes. Ｔリンパ球によるインターフェロンγ分泌の防止または減少に使用するための、請求項１２に記載の医薬組成物。 The pharmaceutical composition according to claim 12, which is used for preventing or reducing interferon gamma secretion by T lymphocytes. 請求項１－１１のいずれか１つに記載の抗体または抗原結合フラグメントをコードする、核酸。 A nucleic acid encoding the antibody or antigen binding fragment according to any one of claims 1-11. 請求項２０に記載の核酸を含む細胞。 A cell containing the nucleic acid according to claim 20. 前記細胞は真核細胞である、請求項２１に記載の細胞。 The cell according to claim 21, wherein the cell is a eukaryotic cell.
JP2020560230A 2018-04-25 2019-04-24 Optimized anti-TL1A antibody Active JP7332627B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023131429A JP2023166402A (en) 2018-04-25 2023-08-10 Optimized anti-tl1a antibodies

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862662605P 2018-04-25 2018-04-25
US62/662,605 2018-04-25
US201862756494P 2018-11-06 2018-11-06
US62/756,494 2018-11-06
PCT/US2019/028987 WO2019209995A2 (en) 2018-04-25 2019-04-24 Optimized anti-tl1a antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023131429A Division JP2023166402A (en) 2018-04-25 2023-08-10 Optimized anti-tl1a antibodies

Publications (3)

Publication Number Publication Date
JP2021521843A JP2021521843A (en) 2021-08-30
JPWO2019209995A5 true JPWO2019209995A5 (en) 2022-05-02
JP7332627B2 JP7332627B2 (en) 2023-08-23

Family

ID=68295788

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020560230A Active JP7332627B2 (en) 2018-04-25 2019-04-24 Optimized anti-TL1A antibody
JP2023131429A Pending JP2023166402A (en) 2018-04-25 2023-08-10 Optimized anti-tl1a antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023131429A Pending JP2023166402A (en) 2018-04-25 2023-08-10 Optimized anti-tl1a antibodies

Country Status (10)

Country Link
US (4) US20210070871A1 (en)
EP (1) EP3784699A4 (en)
JP (2) JP7332627B2 (en)
KR (1) KR20210005169A (en)
CN (1) CN112585165A (en)
AU (1) AU2019261426A1 (en)
CA (1) CA3098374A1 (en)
MA (1) MA52366A (en)
TW (1) TWI842707B (en)
WO (1) WO2019209995A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY191324A (en) * 2016-10-26 2022-06-15 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
MA52366A (en) 2018-04-25 2021-03-03 Prometheus Biosciences Inc OPTIMIZED ANTI-TL1A ANTIBODIES
JP2022533956A (en) 2019-05-14 2022-07-27 プロメテウス バイオサイエンシーズ，インク． Methods, Systems, and Devices for Selecting TL1A Patients
AU2020371725A1 (en) 2019-10-24 2022-05-26 Cedars-Sinai Medical Center Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof
TW202132338A (en) * 2019-10-24 2021-09-01 美商普羅米修斯生物科學股份有限公司 Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
BR112022025667A2 (en) * 2020-06-26 2023-03-07 Pfizer METHODS OF TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH TL1A ANTIBODIES
BR112023009172A2 (en) * 2020-11-13 2023-10-03 Cedars Sinai Medical Center METHODS, SYSTEMS AND KITS FOR TREATMENT OF INFLAMMATORY DISEASES TAILORED TO TL1A
EP4294444A1 (en) * 2021-02-18 2023-12-27 Prometheus Biosciences, Inc. Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
WO2024037621A1 (en) * 2022-08-19 2024-02-22 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Ptk7-binding protein and use thereof

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (en) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド Modifications of or for denatured antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DK0814159T3 (en) 1990-08-29 2005-10-24 Genpharm Int Transgenic, non-human animals capable of forming heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
ES2313867T3 (en) 1991-12-02 2009-03-16 Medical Research Council ANTI-AUTO ANTIBODY PRODUCTION OF ANTIBODY SEGMENT REPERTORIES EXPRESSED ON THE PAYMENT SURFACE.
GB9325182D0 (en) 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
US6824767B2 (en) 1994-11-07 2004-11-30 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US20030198640A1 (en) 1994-11-07 2003-10-23 Human Genome Sciences, Inc. Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta
WO2000066608A1 (en) 1999-04-30 2000-11-09 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US6599719B2 (en) 1994-11-07 2003-07-29 Human Genome Sciences, Inc. Nucleic acid molecules encoding tumor necrosis factor-gamma-alpha
DE69434988T2 (en) 1994-11-07 2008-03-06 Human Genome Sciences, Inc. Tumor necrosis FACTOR GAMMA
US20030129189A1 (en) 1994-11-07 2003-07-10 Guo-Liang Yu Tumor necrosis factor-gamma
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7820798B2 (en) 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
DK0859841T3 (en) 1995-08-18 2002-09-09 Morphosys Ag Protein / (poly) peptide libraries
US6828422B1 (en) 1995-08-18 2004-12-07 Morphosys Ag Protein/(poly)peptide libraries
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
DK1034298T3 (en) 1997-12-05 2012-01-30 Scripps Research Inst Humanization of murine antibody
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
EP1071458A4 (en) 1998-03-13 2005-02-16 Dana Farber Cancer Inst Inc Humanized antibody and uses thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2001002588A2 (en) 1999-07-02 2001-01-11 Morphosys Ag Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests
US6399857B1 (en) * 1999-09-22 2002-06-04 Paradigm Genetics, Inc. Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US6571638B2 (en) 2000-06-30 2003-06-03 Sawtek, Inc. Surface-acoustic-wave pressure sensor and associated methods
WO2002004643A1 (en) 2000-07-07 2002-01-17 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US6824989B1 (en) 2000-09-01 2004-11-30 Upstate Biotechnology, Inc. Recombinant monoclonal antibody to phosphotyrosine-containing proteins
CA2391711A1 (en) 2001-06-26 2002-12-26 University Of Guelph Non-radioactive assay of lipopolysaccharide kinases
AU2003208415B2 (en) * 2002-02-14 2009-05-28 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
US7314974B2 (en) * 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20090042291A1 (en) 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
DE60336406D1 (en) 2002-10-16 2011-04-28 Purdue Pharma Lp ANTIBODIES BINDING TO CELL ASSOCIATED CA 125 / 0722P, AND METHOD FOR THEIR USE
WO2004050836A2 (en) 2002-11-27 2004-06-17 Biogen Idec Ma Inc. Humanized antibodies against monocyte chemotactic proteins
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US20050101889A1 (en) 2003-11-06 2005-05-12 Freeman Gary A. Using chest velocity to process physiological signals to remove chest compression artifacts
WO2006017173A1 (en) * 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
TWI380996B (en) 2004-09-17 2013-01-01 Hoffmann La Roche Anti-ox40l antibodies
MX2007013609A (en) 2005-05-06 2008-01-24 Zymogenetics Inc Il-31 monoclonal antibodies and methods of use.
EP1885388B1 (en) 2005-05-10 2013-09-11 Biogen Idec MA Inc. Treating and evaluating inflammatory disorders
US20090317388A1 (en) 2005-05-25 2009-12-24 Linda Burkly Tl1a in treatment of disease
CN103146708A (en) * 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40 binding proteins
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AU2006284922B2 (en) 2005-08-30 2012-01-19 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins
KR101571027B1 (en) 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 Single-chain multivalent binding proteins with effector function
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
US9896511B2 (en) * 2007-01-10 2018-02-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
US20110217310A1 (en) 2007-01-10 2011-09-08 Siegel Richard M Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology
WO2008106579A2 (en) 2007-02-28 2008-09-04 Cedars-Sinai Medical Center The role of il-12, il-23 and il-17 receptors in inflammatory bowel disease
EA020886B1 (en) 2007-11-13 2015-02-27 ТЕВА БИОФАРМАСЬЮТИКАЛЗ ЮЭсЭй, ИНК. Humanized antibodies against tl1a
CN101469270B (en) 2007-12-27 2012-08-22 牛斌 Industrial continuous plastic cracker
WO2009092014A1 (en) 2008-01-18 2009-07-23 Gagnon Peter S Enhanced purification of antibodies and antibody fragments by apatite chromatography
CA2737636A1 (en) 2008-09-29 2010-04-01 Roche Glycart Ag Antibodies against human il17 and uses thereof
CA2756186A1 (en) 2009-03-24 2010-09-30 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against light and uses thereof
DK2462165T3 (en) 2009-08-03 2016-08-29 Univ Miami Method for in vivo proliferation of regulatory T cells
WO2011106707A2 (en) 2010-02-26 2011-09-01 Human Genome Sciences, Inc. Antibodies that specifically bind to dr3
KR101603001B1 (en) 2010-08-25 2016-03-11 에프. 호프만-라 로슈 아게 Antibodies against il-18r1 and uses thereof
CA2810465C (en) 2010-09-16 2018-10-02 Baliopharm Ag Anti-hutnfr1 antibody
US8766034B2 (en) 2010-09-22 2014-07-01 Cedars-Sinai Medical Center TL1A model of inflammation fibrosis and autoimmunity
JO3375B1 (en) 2010-11-08 2019-03-13 Regeneron Pharma Human antibodies to human tnf-like ligand 1a (tl1a)
US9902996B2 (en) 2011-02-11 2018-02-27 Cedars-Sinai Medical Center Methods of predicting the need for surgery in crohn's disease
KR20140104344A (en) 2011-05-20 2014-08-28 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 시크리터리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시스 Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
KR102051014B1 (en) 2011-06-03 2019-12-04 조마 테크놀로지 리미티드 Antibodies specific for tgf-beta
CA2839539C (en) 2011-06-30 2021-06-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
EP3495389A1 (en) 2011-09-30 2019-06-12 Teva Pharmaceuticals Australia Pty Ltd Antibodies against tl1a and uses thereof
KR20140100532A (en) 2011-11-30 2014-08-14 추가이 세이야쿠 가부시키가이샤 Drug containing carrier into cell for forming immune complex
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
KR20150037959A (en) 2012-08-02 2015-04-08 에프. 호프만-라 로슈 아게 Method for producing monomeric and multimeric molecules and uses thereof
PL2880170T3 (en) 2012-08-02 2017-02-28 F.Hoffmann-La Roche Ag METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF
WO2014051109A1 (en) * 2012-09-28 2014-04-03 協和発酵キリン株式会社 Anti-human bmp9 antibody and treatment agent for ectopic ossification disease containing said antibody as active ingredient
CN105102618B (en) 2012-12-27 2018-04-17 中外制药株式会社 heterodimerization polypeptide
CN105102067B (en) 2013-01-02 2020-03-03 艾科诺斯科技股份有限公司 Antibodies that bind TL1A and uses thereof
US10017543B2 (en) 2013-03-13 2018-07-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
ES2699599T3 (en) 2013-03-15 2019-02-11 Abbvie Biotherapeutics Inc Fc variants
BR112015023752B1 (en) 2013-03-15 2023-11-14 Zyngenia, Inc. MODULAR RECOGNITION DOMAIN (MRD), COMPLEX COMPRISING MRD AND CETUXIMAB, USES OF THE COMPLEX TO INHIBIT ANGIOGENESIS AND TREAT CANCER AND PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPLEX
SG10201708143QA (en) * 2013-06-06 2017-11-29 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
US10316083B2 (en) 2013-07-19 2019-06-11 Cedars-Sinai Medical Center Signature of TL1A (TNFSF15) signaling pathway
SI3702373T1 (en) 2013-09-13 2022-11-30 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics
CA3056647A1 (en) 2013-11-13 2015-05-21 Robert ARCH Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
EP3131917B1 (en) * 2014-04-18 2020-06-17 The Board of Trustees of the Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd99
MX2016014346A (en) 2014-05-02 2017-04-27 Teva Pharma Treatment of crohn's disease with delayed-release 6-mercaptopurine.
US10392438B2 (en) 2014-05-16 2019-08-27 Pfizer Inc. Bispecific antibodies
US10160805B2 (en) 2014-07-11 2018-12-25 New York University Methods of treating inflammatory bowel disease by administering tumor necrosis factor-like ligand 1A or an agonistic death-domain receptor 3 antibody
CN113372434B (en) 2014-11-14 2024-06-04 豪夫迈·罗氏有限公司 Antigen binding molecules comprising trimers of TNF family ligands
MA41460A (en) 2015-02-03 2017-12-12 Oncomed Pharm Inc TNFRSF LIAISON AGENTS AND THEIR USES
EP3277305B1 (en) 2015-03-31 2021-07-21 F. Hoffmann-La Roche AG Antigen binding molecules comprising a trimeric tnf family ligand
EP3280439A1 (en) * 2015-04-07 2018-02-14 INSERM - Institut National de la Santé et de la Recherche Médicale Anti-pd-l1 immunotoxin for use in therapy
US10647756B2 (en) 2015-05-18 2020-05-12 Pfizer Inc. Humanized antibodies
JP6932700B2 (en) 2015-09-15 2021-09-08 アムジエン・インコーポレーテツド Tetravalent bispecific antigen-binding proteins and tetravalent quadrispecific antigen-binding proteins, and their use
TWI703158B (en) 2015-09-18 2020-09-01 美商希佛隆公司 Antibodies that specifically bind to tl1a
MA43017A (en) 2015-10-02 2018-08-08 Hoffmann La Roche BISPECIFIC ANTIBODIES SPECIFIC TO A TNF CO-STIMULATION RECEPTOR
WO2017077715A1 (en) 2015-11-02 2017-05-11 La Jolla Institute For Allergy & Immunology Method and medicament for treating airway and/or lung diseases
ITUB20155097A1 (en) * 2015-11-05 2017-05-05 Biouniversa Srl Humanized anti-BAG3 antibodies
CR20180365A (en) 2015-12-16 2018-09-28 Amgen Inc PROTEINS OF UNION TO THE ANTI-TL1A / ANTI-TNF-a BISPECTIVE ANTIGEN AND ITS USES
TWI776808B (en) 2016-04-29 2022-09-11 美商輝瑞大藥廠 Interferon beta antibodies and uses thereof
AU2017264578A1 (en) 2016-05-09 2019-01-03 Bristol-Myers Squibb Company TL1A antibodies and uses thereof
KR102359192B1 (en) 2016-07-25 2022-02-04 세파론, 인코포레이티드 Affinity Chromatography Wash Buffer
MY191324A (en) 2016-10-26 2022-06-15 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
US20190343425A1 (en) 2016-12-14 2019-11-14 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
WO2019074973A2 (en) 2017-10-10 2019-04-18 Sanofi Anti-cd38 antibodies and methods of use
WO2019121906A1 (en) 2017-12-19 2019-06-27 F-Star Beta Limited Specific pd-l1 binding sequences inserted in a ch3 domain
MA52366A (en) 2018-04-25 2021-03-03 Prometheus Biosciences Inc OPTIMIZED ANTI-TL1A ANTIBODIES
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
WO2020011966A1 (en) 2018-07-12 2020-01-16 F-Star Beta Limited Antibody molecules that bind cd137 and ox40
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
JP7360440B2 (en) 2018-07-12 2023-10-12 エフ－スター セラピューティクス リミテッド Antibody molecules that bind to PD-L1 and CD137
AU2019357467A1 (en) 2018-10-09 2021-05-27 Sanofi Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection
JP2022505871A (en) 2018-10-23 2022-01-14 ドラゴンフライ セラピューティクス， インコーポレイテッド Heterodimer FC fusion protein
TW202132338A (en) 2019-10-24 2021-09-01 美商普羅米修斯生物科學股份有限公司 Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
AU2020371725A1 (en) 2019-10-24 2022-05-26 Cedars-Sinai Medical Center Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof
BR112022025667A2 (en) 2020-06-26 2023-03-07 Pfizer METHODS OF TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH TL1A ANTIBODIES

Similar Documents

Publication Publication Date Title
JP2022177090A5 (en)
JP2024020298A5 (en)
JP2020079252A5 (en)
HRP20200583T1 (en) Neutralizing antibodies to gp120 and their use
JP2020518600A5 (en)
JP2017514461A5 (en)
JP2020518598A5 (en)
JP2018535650A5 (en)
JP2018035138A5 (en)
JP2022191383A5 (en)
JP2023002562A5 (en)
RU2012112829A (en) ANTI-GITR-ANTIBODIES
RU2009129403A (en) ANTIBODIES NEUTRALIZING HUMAN CYTOMEGALOVIRUS AND THEIR APPLICATION
JP2012532851A5 (en)
JP2016538876A5 (en)
RU2020130795A (en) NEUTRALIZING ANTIBODIES TO ENV HIV-1 AND THEIR USE
JP2024024114A5 (en)
JP2023093753A5 (en)
JP2020522280A5 (en)
JP2018522540A5 (en)
RU2020127196A (en) ANTIBODY AGAINST 4-1BB, ITS ANTIGEN-BINDING FRAGMENT AND ITS MEDICAL APPLICATIONS
JPWO2021217004A5 (en)
JP2020522281A5 (en)
JP2020513759A5 (en)
JP2019528046A5 (en)